Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort

Table 2 Associations between MMPs/TIMPs and IPF versus control status, ordered by corrected p-value

Protein (pg/mL)	Group	gMean	RatioIPF:control %^a	Corrected p-value^b
MMP8	Control	13.68
MMP8	IPF	55.41	4.05	<.0001
MMP9	Control	2801.98
MMP9	IPF	5793.87	2.07	<.0001
TIMP1	Control	326,688.87
TIMP1	IPF	456,465.47	1.40	<.0001
MMP1	Control	11.77
MMP1	IPF	24.88	2.11	<.0001
TIMP4	Control	3414.36
TIMP4	IPF	4067.08	1.19	0.0004
MMP7	Control	196.39
MMP7	IPF	234.88	1.20	0.0008
MMP2	Control	22,709.02
MMP2	IPF	29,111.36	1.28	0.0024
MMP13	Control	25.20
MMP13	IPF	37.55	1.49	0.0024
MMP12	Control	41.85
MMP12	IPF	58.16	1.39	0.0097
MMP3	Control	5393.62
MMP3	IPF	6370.79	1.18	0.0164
TIMP2	Control	134,417.53
TIMP2	IPF	141,289.58	1.05	0.1029

gMean geometric mean
^aRepresents the ratio of the geometric mean concentration for each protein in patients with IPF relative to controls. Model includes IPF status (yes/no) as factor
^bp-values were corrected for multiple comparisons using the Benjamini-Hochberg method to control the false discovery rate at 5%

ISSN: 1471-2466